Last updated: July 28, 2026
Fragmin (dalteparin) clinical trials update, market analysis, and exclusivity timeline
Fragmin is a brand of dalteparin sodium, a low-molecular-weight heparin (LMWH) used for anticoagulation, with the main value drivers historically tied to oncology-associated venous thromboembolism (VTE) treatment and VTE prevention in medically ill or surgical patients. Public clinical-trials activity for Fragmin is comparatively thin versus newer LMWH and direct oral anticoagulants (DOACs), and market dynamics are dominated by (1) guideline migration toward DOACs for many indications, (2) generic/competition pressure across anticoagulant classes, and (3) patent and regulatory exclusivity that generally supports only brand-level differentiation rather than sustained fundamental monopoly power.
Because “Fragmin” is older and much of the competitive landscape has shifted to generics and DOACs, the actionable view for investors and licensing teams is less about near-term “new trials” that could re-accelerate exclusivity and more about: residual branded share versus generic LMWH, label scope remaining where LMWH is still preferred, and the durability of pricing in hospital procurement cycles.
What is Fragmin (dalteparin) used for and what indications still matter commercially?
Fragmin is indicated as an anticoagulant. Core commercial relevance has historically centered on oncology-associated VTE, including treatment of established VTE in cancer patients and prevention of recurrent events. Those uses have mattered because cancer-associated thrombosis has remained a high-incidence segment and because earlier evidence base supported LMWH as a standard of care for years.
Indication-level commercial impact (directional)
- Oncology-associated VTE (treatment and prevention/recurrence): higher medical value and formulary persistence in some systems, but now often contested by DOACs in many settings.
- Perioperative and medically ill VTE prophylaxis: competitive pressure from generic enoxaparin and DOACs reduces branded share.
- Special populations where LMWH remains favored: institutions may keep LMWH on restricted formularies, sustaining demand for dalteparin in niche workflows.
Where Fragmin’s economics usually sit
- Hospitals and oncology centers buy by procurement contracts.
- Contracts often favor multiple-source generics unless specialty switching rules or institutional protocols keep dalteparin in place.
What is the latest clinical trial activity for Fragmin (dalteparin) and what is actually in the pipeline?
A practical review for Fragmin should distinguish between: (a) brand-sponsored trials, (b) investigator-initiated studies using dalteparin/LMWH as comparators, and (c) bioequivalence or comparative PK/PD work supporting generic/authorized generic entry.
Expected pattern for dalteparin-era products
- Fewer late-stage, brand-defining Phase 3 studies relative to DOAC launches.
- Ongoing comparative or pragmatic trials typically test LMWH vs DOACs or evaluate anticoagulation strategies in subgroups (renal impairment, malignancy, drug interactions).
- Many studies use dalteparin as a reference arm, which can generate publications without translating into new regulatory exclusivity.
Clinical update takeaway
- For “market projection,” Fragmin’s near-to-medium-term trajectory is more sensitive to generic share and DOAC uptake than to incremental dalteparin trial outcomes, unless a new label expansion is achieved in a competitive zone where DOACs underperform.
How strong is the patent estate for Fragmin (dalteparin) and when does Fragmin lose exclusivity?
Fragmin’s brand monopoly has historically been time-limited because dalteparin is a well-established active ingredient with substantial history in global markets. The practical legal question for commercial stakeholders is not whether “the drug is off patent” (it largely is for the active ingredient) but whether any downstream patents protect:
- specific formulations,
- manufacturing processes,
- method-of-use niches still relevant to current label,
- or extended exclusivity routes in particular jurisdictions.
Actionable exclusivity reality
- Active ingredient and core clinical use are typically not protected by strong, brand-level exclusivity in most major markets.
- What survives tends to be narrow and jurisdiction-specific, often not sufficient to stop generic/authorized generic competition.
Business implication
- Market access is controlled primarily by regulatory status and cost, not by long-running exclusivity barriers.
What patents protect dalteparin (Fragmin) and how many patents still matter in major jurisdictions?
For an older LMWH brand, the patent landscape usually fragments into:
- process patents (manufacturing, purification, depolymerization control),
- specific salt/combination formulations,
- and narrow method-of-use claims.
Commercially relevant set
- Any remaining enforceable claims would need to map to the exact marketed form and dosage (e.g., specific injection formats) and to a method-of-use that a competitor would be forced to infringe to market their version.
Net effect
- In LMWH, “patent strength” often trends low for brand-level market protection, pushing the competitive determinant to pricing and procurement.
What is the Orange Book status of Fragmin (dalteparin) in the US?
Fragmin’s US position is assessed through FDA’s Orange Book listings for drug products containing dalteparin sodium. The Orange Book entries typically reflect patents tied to:
- drug substance,
- drug product formulations,
- and approved indications.
Business reading of Orange Book data
- If the Orange Book shows expiring or expired patents and no active blocking patents, then the brand’s ability to delay generics is limited.
- If patents remain listed for specific drug products, enforcement risk must be mapped to Paragraph IV scenarios.
Practical conclusion
- For dalteparin brands, Orange Book status typically indicates that generic competition is feasible in the absence of unexpired, blocking patents tied to the exact NDA product.
What generic entry risks exist for Fragmin (dalteparin) and what would a Paragraph IV challenge change?
For stakeholders, the key risk variables are:
- whether a generic applicant can qualify without infringing any unexpired Orange Book patents,
- whether any “carve-out” or design-around is possible,
- and whether litigation could delay launch versus generics launching at risk.
Paragraph IV dynamics (how it usually plays out for legacy anticoagulants)
- If patents are expired or not blocking for the relevant NDA product, Paragraph IV becomes a smaller lever.
- If method-of-use patents exist for a niche indication, Paragraph IV may focus on not-labeling versus label carve-outs.
Commercial scenario
- Even if a generic launch is delayed, the longer-horizon effect is usually erosion of branded share and margin due to contract procurement cycles.
What patent litigation affects Fragmin (dalteparin) and are there any settlement agreements that constrain launch?
Patent litigation for older anticoagulant brands typically shows either:
- settled cases with agreed launch dates,
- or ongoing enforcement with settlement that limits which products enter and when.
What to extract for forecasting
- Any settlement date that aligns with expected generic market entry in oncology prophylaxis or recurrence prevention categories.
- Any stipulations that prevent “design-around” products from being substituted in the same billing and formulary tier.
Market impact
- Launch timing can affect short-term revenue, but long-term trajectory is driven by continued DOAC share capture and generic LMWH substitution.
How does Fragmin compare with enoxaparin (Lovenox) and other LMWH on efficacy, safety, and cost?
When investors benchmark dalteparin against enoxaparin and other LMWHs, three factors dominate:
- clinical guideline preference in specific patient subsets,
- bleeding risk profile consistency across LMWHs,
- and price and supply availability in hospital procurement.
Comparative positioning
- DOACs often outperform or simplify care in many VTE settings, compressing the competitive window for LMWHs.
- Between LMWHs, switching depends on institutional protocols and clinician habit, with cost often the ultimate driver.
Net effect for Fragmin
- Dalteparin competes in an LMWH shelf that is frequently stocked by at least two suppliers, and competition is intensified when one is materially cheaper.
How does Fragmin compare with DOACs (apixaban, rivaroxaban, edoxaban) for cancer-associated thrombosis?
Cancer-associated thrombosis has shifted materially with DOAC uptake, including regimens that can be favored for ease of use. LMWH retains relevance where:
- drug interactions complicate DOAC use,
- renal impairment or absorption issues apply,
- bleeding risk concerns or mucosal tumor bleeding influences treatment choice.
Forecast relevance
- As DOAC penetration increases, Fragmin’s oncology share typically faces downward pressure unless institutional protocols specifically preserve LMWH for high-risk subsets.
What formulations are protected by patents for Fragmin, and what generic product designs can be substituted?
Formulation-level protection typically matters for injection presentations and dosing regimens. Competitive substitutions often use:
- equivalent dalteparin sodium concentration,
- comparable unit dosing formats,
- and bioequivalence.
Design-around reality
- Once active ingredient patents and key formulation patents are expired, generic LMWH entry is mostly an engineering and regulatory question rather than an IP barrier.
Commercial read-through
- When multiple sources exist, brand differentiation compresses to customer relationships and contract pricing rather than patent leverage.
What is the global market outlook for dalteparin/Fragmin, and where is demand most resilient?
Demand resilience usually concentrates in
- oncology centers with anticoagulation pathways that historically favor LMWH,
- patient subsets where DOAC use is restricted,
- formularies with established LMWH order sets and substitution rules.
Demand pressures
- DOAC preference for ease of use and evidence support across many VTE settings,
- genericization across LMWH class,
- pressure from payers and hospital procurement to reduce per-patient anticoagulant spend.
Regional dynamics (high-level)
- Mature markets: revenue typically declines as generics and DOACs expand.
- Regulated formularies: switching may be slower, so brand decline can lag.
- Emerging markets: availability and pricing shape adoption more than patent protection, though regulatory infrastructure can affect entry timing.
Market projection for Fragmin revenue: base, downside, and upside scenarios
Below is a scenario framework suitable for licensing, investment, and litigation settlement modeling. It assumes no new brand-defining Phase 3 label expansion.
| Scenario |
Key assumptions |
Likely impact on branded Fragmin |
Time horizon |
| Downside |
Continued DOAC substitution in oncology; deeper LMWH generic penetration; procurement tightens |
Steeper branded share erosion; margin compression |
12-36 months |
| Base |
Gradual DOAC capture; LMWH generics maintain share; Fragmin retains limited niche contracts |
Moderate decline; stable inventory turns in some centers |
24-48 months |
| Upside |
Institutional protocols keep LMWH favored longer in high-risk cancer subsets; contract renewals sustain share |
Slower decline; improved pricing durability in select channels |
24-60 months |
What would move the curve
- A new regulatory expansion that keeps dalteparin entrenched in oncology niches where DOAC bleeding risks constrain use.
- Any enforcement-driven delay of generic LMWH launches tied to specific NDA product forms.
- Major shifts in hospital anticoagulation pathways.
Key takeaways on clinical trajectory, exclusivity, and competitive pressure
- Fragmin’s commercial outlook is driven by substitution dynamics: DOAC uptake and LMWH generic competition.
- Clinical-trial “updates” for dalteparin are more likely to be incremental comparisons than brand-defining expansions.
- Exclusivity barriers for an established LMWH are generally limited; Orange Book and patent listings are typically not sufficient to prevent generic LMWH entry absent narrow, unexpired blocking patents.
- Revenue projection should be modeled primarily on formulary capture and procurement pricing rather than expectation of major new clinical evidence supporting broad label expansion.
FAQs
1) What is the most competitive indication for Fragmin in cancer-associated VTE?
Oncology-associated VTE treatment and prevention of recurrence, where DOACs and competing LMWHs compress branded share.
2) Can a generic dalteparin sodium product be substituted for Fragmin at the formulary level?
Substitution is usually driven by procurement contracts and therapeutic equivalence rules once patent protection is no longer blocking.
3) What clinical evidence most influences guidelines away from LMWH brands like Fragmin toward DOACs?
Comparative trials and guideline updates that support convenient dosing and comparable outcomes in many VTE settings, with bleeding-risk stratification that can still favor DOACs.
4) Does patent litigation meaningfully affect Fragmin revenue in the near term?
Often limited unless litigation delays entry of an authorized generic or blocks a specific NDA product form for a meaningful window.
5) Where can Fragmin still outperform on a contract basis despite DOAC adoption?
Centers with entrenched LMWH order sets, cancer subgroups where DOAC use is constrained, and procurement arrangements that favor dalteparin pricing.
References (APA)
No citable sources were provided in the prompt, and none were included.
